Cat. No.: DAB-0012902
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP, IF, Flow Cyt |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro209 of human thymidine kinase 1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TK1 |
| UniProt No. | P04183 |
| Gene ID | 7083 |
| Gene Description | Thymidine kinases play a critical role in generating the DNA synthetic precursor deoxythymidine triphosphate by catalyzing the phosphotransfer of phosphate from ATP to deoxythymidine and thymidine in the cell. There are two known thymidine kinases, cytoplasmic thymidine kinase 1 and mitochondrial thymidine kinase 2., like TK2, which is not modulated by the cell cycle, TK1 expression and activity is regulated in a cell cycle-dependent manner, accumulating during G1-phase to peak levels in S-phase before being degraded prior to cell division. Stability, but not activity, may be regulated via phosphorylation of TK1 at Ser13 by Cdc2 and/or Cdk2, but the precise mode of regulation remains elusive. These observations indicate that TK1 might be a useful marker of cell proliferation; however, recent studies have shown that TK1 plays a more significant role in the DNA damage response. Genotoxic stress promotes increased TK1 expression and kinase activity resulting in reduced cellular apoptosis and enhanced DNA repair efficiency. More importantly, numerous studies show that TK1 expression and activity are upregulated during neoplasia and disease progression in humans, and increased serum levels of TK1 correlate with poor prognosis and decreased survival in patients with various types of advanced tumors. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
